Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

NCT01345253 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01345253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01345253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2011
Completion date
September 21, 2018
Enrollment
709 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus